Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis
Abstract Background Oclacitinib (OCL), a Janus kinase inhibitor, is a novel immunomodulatory/immunosuppressive agent which is an approved as the first-line treatment for atopic dermatitis (AD) in dogs. The aim of the study was to investigate the effects of OCL on CD4+ and CD8+ T cells and their sele...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2024-10-01
|
| coleção: | BMC Veterinary Research |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12917-024-04340-0 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|